Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P18054

UPID:
LOX12_HUMAN

ALTERNATIVE NAMES:
Arachidonate (12S)-lipoxygenase; Arachidonate (15S)-lipoxygenase; Linoleate (13S)-lipoxygenase; Lipoxin synthase 12-LO; Platelet-type lipoxygenase 12

ALTERNATIVE UPACC:
P18054; O95569; Q6ISF8; Q9UQM4

BACKGROUND:
The enzyme Polyunsaturated fatty acid lipoxygenase ALOX12 is instrumental in converting arachidonate and other polyunsaturated fatty acids into lipid hydroperoxides, leading to the formation of compounds with significant roles in inflammation and cell signaling. This includes the generation of specialized pro-resolving mediators like resolvin D5, which are vital for resolving inflammation and preventing chronic inflammatory diseases.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Polyunsaturated fatty acid lipoxygenase ALOX12 could open doors to potential therapeutic strategies. By modulating ALOX12 activity, it is possible to influence the production of bioactive lipids involved in inflammation and cancer, offering pathways to treat or manage conditions like esophageal and colorectal cancers.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.